ID   DH82
AC   CVCL_2018
SY   DH-82; DH 82
DR   CLO; CLO_0002775
DR   CLDB; cl1058
DR   CLDB; cl1059
DR   ATCC; CRL-10389
DR   BCRC; 60110
DR   BCRJ; 0077
DR   CCRID; 1101CAN-PUMC000818
DR   CCRID; 3101CANTCO3
DR   CLS; 305003
DR   ECACC; 94062922
DR   GEO; GSM1974787
DR   ICLC; ATL96008
DR   KCB; KCB 2014070YJ
DR   Wikidata; Q54831065
RX   Patent=US5192679;
RX   PubMed=3350786;
RX   PubMed=11377712;
RX   PubMed=11585095;
RX   PubMed=12234001;
RX   PubMed=21908323;
RX   PubMed=25534080;
RX   PubMed=26842912;
RX   PubMed=27197945;
RX   PubMed=27257868;
RX   PubMed=28620374;
RX   PubMed=31175136;
RX   PubMed=33389257;
WW   https://web.archive.org/web/20201109215324/www.infarktforschung.de/macrophages_cell_lines.html
CC   Part of: FACC canine tumor cell line panel.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10389.
CC   Characteristics: Can be infected by Trypanosoma cruzi which can then replicate and differentiate inside the cell.
CC   Characteristics: Susceptible to infection by Ehrlichia ruminantium (PubMed=11585095; PubMed=12234001).
CC   Virology: Supports the replication of equine infectious anemia virus (EIAV) (PubMed=11377712).
CC   Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257).
CC   Doubling time: 26 hours (PubMed=27257868).
CC   Sequence variation: Mutation; VGNC; 45168; PTPN11; Simple; p.Gly503Val (c.1508G>T); Zygosity=Homozygous (PubMed=31175136).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Breed/subspecies: Golden Retriever.
ST   Source(s): PubMed=27197945; PubMed=31175136
ST   Dog FHC2010: 231
ST   Dog FHC2054: 156,168
ST   Dog FHC2079: 275
ST   Dog PEZ1: 119,123
ST   Dog PEZ3: 121
ST   Dog PEZ5: 107
ST   Dog PEZ6: 179
ST   Dog PEZ8: 232,240
ST   Dog PEZ12: 270,285
ST   Dog PEZ20: 176
DI   NCIt; C128125; Canine histiocytic sarcoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Male
AG   10Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 23
//
RX   Patent=US5192679;
RA   Dawson J.E., Rikihisa Y.;
RT   "Growing Ehrlichia species in a continuous cell line.";
RL   Patent number US5192679, 09-Mar-1993.
//
RX   PubMed=3350786; DOI=10.1007/BF02623551;
RA   Wellman M.L., Krakowka S., Jacobs R.M., Kociba G.J.;
RT   "A macrophage-monocyte cell line from a dog with malignant
RT   histiocytosis.";
RL   In Vitro Cell. Dev. Biol. 24:223-229(1988).
//
RX   PubMed=11377712; DOI=10.1016/s0166-0934(01)00288-9;
RA   Hines R., Maury W.;
RT   "DH82 cells: a macrophage cell line for the replication and study of
RT   equine infectious anemia virus.";
RL   J. Virol. Methods 95:47-56(2001).
//
RX   PubMed=11585095;
RA   Zweygarth E., Josemans A.I.;
RT   "Continuous in vitro propagation of Cowdria ruminantium (Welgevonden
RT   stock) in a canine macrophage-monocyte cell line.";
RL   Onderstepoort J. Vet. Res. 68:155-157(2001).
//
RX   PubMed=12234001;
RA   Zweygarth E., Josemans A.I., Van Strijp M.F., Van Heerden H.,
RA   Allsopp M.T.E.P., Allsopp B.A.;
RT   "The Kumm isolate of Ehrlichia ruminantium: in vitro isolation,
RT   propagation and characterization.";
RL   Onderstepoort J. Vet. Res. 69:147-153(2002).
//
RX   PubMed=21908323; DOI=10.1177/1040638711408064;
RA   O'Donoghue L.E., Rivest J.P., Duval D.L.;
RT   "Polymerase chain reaction-based species verification and
RT   microsatellite analysis for canine cell line validation.";
RL   J. Vet. Diagn. Invest. 23:780-785(2011).
//
RX   PubMed=25534080; DOI=10.1016/j.vetimm.2014.11.006;
RA   Heinrich F., Contioso V.B., Stein V.M., Carlson R., Tipold A.,
RA   Ulrich R., Puff C., Baumgartner W., Spitzbarth I.;
RT   "Passage-dependent morphological and phenotypical changes of a canine
RT   histiocytic sarcoma cell line (DH82 cells).";
RL   Vet. Immunol. Immunopathol. 163:86-92(2015).
//
RX   PubMed=26842912; DOI=10.1111/vco.12197;
RA   Hartley G., Faulhaber E., Caldwell A., Coy J., Kurihara J., Guth A.,
RA   Regan D.P., Dow S.W.;
RT   "Immune regulation of canine tumour and macrophage PD-L1 expression.";
RL   Vet. Comp. Oncol. 15:534-549(2017).
//
RX   PubMed=27197945; DOI=10.1111/vco.12192;
RA   Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.;
RT   "The Flint Animal Cancer Center (FACC) canine tumour cell line panel:
RT   a resource for veterinary drug discovery, comparative oncology and
RT   translational medicine.";
RL   Vet. Comp. Oncol. 15:481-492(2017).
//
RX   PubMed=27257868; DOI=10.1371/journal.pone.0156689;
RA   Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.;
RT   "Intrinsic radiosensitivity and cellular characterization of 27 canine
RT   cancer cell lines.";
RL   PLoS ONE 11:E0156689-E0156689(2016).
//
RX   PubMed=28620374; DOI=10.3389/fimmu.2017.00604;
RA   Mendonca P.H.B., da Rocha R.F.D.B., de Braz Moraes J.B.,
RA   LaRocque-de-Freitas I.F., Logullo J., Morrot A., Nunes M.P.,
RA   Freire-de-Lima C.G., Decote-Ricardo D.;
RT   "Canine macrophage DH82 cell line as a model to study susceptibility
RT   to Trypanosoma cruzi infection.";
RL   Front. Immunol. 8:604.1-604.11(2017).
//
RX   PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346;
RA   Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.;
RT   "Identifying candidate druggable targets in canine cancer cell lines
RT   using whole exome sequencing.";
RL   Mol. Cancer Ther. 18:1460-1471(2019).
//
RX   PubMed=33389257; DOI=10.1007/s10096-020-04106-0;
RA   Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.;
RT   "Culture of SARS-CoV-2 in a panel of laboratory cell lines,
RT   permissivity, and differences in growth profile.";
RL   Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021).
//